Skip to main content

Blood Test May Provide New Option for Colorectal Cancer Screening

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 3, 2025.

via HealthDay

MONDAY, Feb. 3, 2025 -- A blood-based test (Freenome) may provide a new option for colorectal cancer (CRC) screening in the average-risk U.S. population, according to a study presented at the American Society of Clinical Oncology annual Gastrointestinal Cancers Symposium, held from Jan. 23 to 25 in San Francisco.

Aasma Shaukat, M.D., from the New York University Grossman School of Medicine in New York City, and colleagues previously evaluated clinical performance of an investigational blood-based screening test for detecting molecular signals of advanced colorectal neoplasia (ACN) in an average-risk population. This analysis evaluated how the test would perform in the standard U.S. population, weighting the validation cohort (27,010 participants aged 45 to 85 years) to the U.S. Census sex and age distribution.

The researchers report that after performance was weighted to match U.S. Census sex and age distributions, sensitivity for CRC was 81.1 percent, specificity for those without ACN was 90.4 percent, negative predictive value for those without ACN was 90.5 percent, and positive predictive value for ACN was 15.5 percent. For advanced precancerous lesions, sensitivity was 13.7 percent.

"Additional colorectal cancer screening tests that are convenient, safe, and easy to complete are needed," Shaukat said in a statement. "Until now, we have only had stool-based tests and colonoscopy or sigmoidoscopy. A blood test has the potential for improving colorectal cancer screening rates."

Several authors disclosed financial ties to Freenome.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Rebound Weight Gain Common After Discontinuing Antiobesity Medications

FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...

Patients Face High Out-of-Pocket Costs After Incident Cancer Diagnosis

FRIDAY, July 25, 2025 -- Patients face high out-of-pocket costs (OOPCs) after an incident diagnosis of cancer, with costs increasing with stage of diagnosis, according to a study...

Exposure to PFAS Mixtures Linked to Increased Odds of Type 2 Diabetes

FRIDAY, July 25, 2025 -- In multiethnic populations, exposure to per- and polyfluoroalkyl substance (PFAS) mixtures may be associated with increased odds of type 2 diabetes (T2D)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.